iRhythm price target raised to $230 from $205 at Truist

Truist analyst Richard Newitter raised the firm’s price target on iRhythm (IRTC) to $230 from $205 and keeps a Buy rating on the shares. The company delivered a clean Q3 beat and raise result fueled by core business strength, Zio AT adoption, and progress with innovative channel partners, the analyst tells investors in a research note. The increase in FY25 revenue guidance signals the management’s confidence in broad portfolio momentum going forward, the firm added.